{"title":"在日本人群中发现的罕见和已知CYP2E1等位基因变异的综合功能特征。","authors":"Yuki Ohmori, Eiji Hishinuma, Yuma Suzuki, Akiko Ueda, Caroline Mwendwa Kijogi, Tomoki Nakayoshi, Akifumi Oda, Sakae Saito, Shu Tadaka, Kengo Kinoshita, Yu Sato, Masahiro Hiratsuka","doi":"10.1016/j.bcp.2025.117396","DOIUrl":null,"url":null,"abstract":"<p><p>Cytochrome P450 2E1 (CYP2E1) is a key hepatic enzyme involved in the oxidative metabolism of low-molecular-weight xenobiotics, including drugs, anesthetics, and procarcinogens. Although numerous CYP2E1 genetic variants have been identified, their functional implications remain unclear. In this study, we systematically characterized 25 CYP2E1 variants-22 novel missense variants identified via whole-genome sequencing of 8,380 Japanese individuals, and three PharmVar-defined alleles (*2, *3, and *4). The wild-type and variant enzymes were expressed in 293FT cells, and protein levels were quantified by Western blotting. Enzyme activity was evaluated by measuring chlorzoxazone 6-hydroxylation, and kinetic parameters (Km, Vmax, CLint) were derived from Michaelis-Menten analysis. Five variants exhibited significantly reduced catalytic activity, while two showed increased function. One frameshift variant, Leu447fs, resulted in complete loss of activity. In silico 3D docking simulations using a homology-modeled CYP2E1 structure revealed that several function-altering variants were located near the heme-binding domain or substrate recognition sites. Structural analysis of the Leu133His variant suggested that disruption of hydrogen bonding networks near the heme could underlie its reduced activity. The three known star alleles showed no significant deviation from wild-type activity. These findings provide important mechanistic insights into the functional consequences of rare CYP2E1 variants and underscore the enzyme's structural resilience. Our results offer foundational data for interpreting CYP2E1 genetic variation and support future efforts in personalized medicine through pharmacogenomic profiling.</p>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":" ","pages":"117396"},"PeriodicalIF":5.6000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comprehensive functional characterization of rare and known CYP2E1 allelic variants identified in a Japanese population.\",\"authors\":\"Yuki Ohmori, Eiji Hishinuma, Yuma Suzuki, Akiko Ueda, Caroline Mwendwa Kijogi, Tomoki Nakayoshi, Akifumi Oda, Sakae Saito, Shu Tadaka, Kengo Kinoshita, Yu Sato, Masahiro Hiratsuka\",\"doi\":\"10.1016/j.bcp.2025.117396\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cytochrome P450 2E1 (CYP2E1) is a key hepatic enzyme involved in the oxidative metabolism of low-molecular-weight xenobiotics, including drugs, anesthetics, and procarcinogens. Although numerous CYP2E1 genetic variants have been identified, their functional implications remain unclear. In this study, we systematically characterized 25 CYP2E1 variants-22 novel missense variants identified via whole-genome sequencing of 8,380 Japanese individuals, and three PharmVar-defined alleles (*2, *3, and *4). The wild-type and variant enzymes were expressed in 293FT cells, and protein levels were quantified by Western blotting. Enzyme activity was evaluated by measuring chlorzoxazone 6-hydroxylation, and kinetic parameters (Km, Vmax, CLint) were derived from Michaelis-Menten analysis. Five variants exhibited significantly reduced catalytic activity, while two showed increased function. One frameshift variant, Leu447fs, resulted in complete loss of activity. In silico 3D docking simulations using a homology-modeled CYP2E1 structure revealed that several function-altering variants were located near the heme-binding domain or substrate recognition sites. Structural analysis of the Leu133His variant suggested that disruption of hydrogen bonding networks near the heme could underlie its reduced activity. The three known star alleles showed no significant deviation from wild-type activity. These findings provide important mechanistic insights into the functional consequences of rare CYP2E1 variants and underscore the enzyme's structural resilience. Our results offer foundational data for interpreting CYP2E1 genetic variation and support future efforts in personalized medicine through pharmacogenomic profiling.</p>\",\"PeriodicalId\":8806,\"journal\":{\"name\":\"Biochemical pharmacology\",\"volume\":\" \",\"pages\":\"117396\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemical pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.bcp.2025.117396\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.bcp.2025.117396","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Comprehensive functional characterization of rare and known CYP2E1 allelic variants identified in a Japanese population.
Cytochrome P450 2E1 (CYP2E1) is a key hepatic enzyme involved in the oxidative metabolism of low-molecular-weight xenobiotics, including drugs, anesthetics, and procarcinogens. Although numerous CYP2E1 genetic variants have been identified, their functional implications remain unclear. In this study, we systematically characterized 25 CYP2E1 variants-22 novel missense variants identified via whole-genome sequencing of 8,380 Japanese individuals, and three PharmVar-defined alleles (*2, *3, and *4). The wild-type and variant enzymes were expressed in 293FT cells, and protein levels were quantified by Western blotting. Enzyme activity was evaluated by measuring chlorzoxazone 6-hydroxylation, and kinetic parameters (Km, Vmax, CLint) were derived from Michaelis-Menten analysis. Five variants exhibited significantly reduced catalytic activity, while two showed increased function. One frameshift variant, Leu447fs, resulted in complete loss of activity. In silico 3D docking simulations using a homology-modeled CYP2E1 structure revealed that several function-altering variants were located near the heme-binding domain or substrate recognition sites. Structural analysis of the Leu133His variant suggested that disruption of hydrogen bonding networks near the heme could underlie its reduced activity. The three known star alleles showed no significant deviation from wild-type activity. These findings provide important mechanistic insights into the functional consequences of rare CYP2E1 variants and underscore the enzyme's structural resilience. Our results offer foundational data for interpreting CYP2E1 genetic variation and support future efforts in personalized medicine through pharmacogenomic profiling.
期刊介绍:
Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.
The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.
All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.
While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.